APAC MRDR funding for $5.3 million approved

Great news for the Asia-Pacific (APAC) MRDR that funding for $5.3 million over the next 5 years was approved from Janssen-Cilag Pty Ltd! The APAC MRDR is a sister registry to the MRDR, actively recruiting patients in Korea, Singapore and Malaysia, with Taiwan and China to follow.

The APAC MRDR was established in 2018, has 22 approved sites, and has recruited 555 patients. Funding will allow continued patient and site recruitment, the initiation of sites in Taiwan and China, data consolidation and a focus on research output, and the establishment of the APAC MRDR liquid biopsy biobank - a parallel initiative to the MRDR M1000 Biobank.